Novonesis (Novozymes) B (NSISBC.XD)

DKK 410.0

(-0.89%)

Annual Income Statements

(In DKK)
Breakdown 2023 2022 2021 2020 2019
Revenue 17.89 Billion 17.55 Billion 14.95 Billion 14.01 Billion 14.37 Billion
Cost of Revenue 8.17 Billion 7.96 Billion 6.31 Billion 6.15 Billion 6.38 Billion
Gross Profit 9.72 Billion 9.59 Billion 8.63 Billion 7.85 Billion 7.98 Billion
Operating Expenses 5.74 Billion 4.95 Billion 4.63 Billion 4.27 Billion 4.19 Billion
Selling, General and Administrative Expenses 3.32 Billion 3.19 Billion 2.82 Billion 2.29 Billion 2.45 Billion
Research and Development Expenses 2.01 Billion 2 Billion 2 Billion 1.93 Billion 1.96 Billion
Other Expenses 404 Million - - - -
Cost and Expenses 13.92 Billion 12.91 Billion 10.94 Billion 10.43 Billion 10.57 Billion
Operating Income 3.97 Billion 4.48 Billion 3.89 Billion 3.66 Billion 3.58 Billion
Interest Expense - - - - -
Income Tax Expense 870 Million 870 Million 779 Million 695 Million 644 Million
Earnings before Tax 3.9 Billion 4.55 Billion 3.92 Billion 3.52 Billion 3.79 Billion
Net Income 3.02 Billion 3.67 Billion 3.14 Billion 2.82 Billion 3.15 Billion
Earnings Per Share Basic 10.88 13.19 11.23 10.02 11.01
Earnings Per Share Diluted 10.88 13.19 11.23 10.02 11.01
Weighted Average Shares Outstanding 277.94 Million 278.69 Million 280.14 Million 281.93 Million 286.46 Million
Weighted Average Shares Outstanding (Diluted) 277.87 Million 278.73 Million 280.22 Million 282.02 Million 286.55 Million
Gross Margin 0.54 0.55 0.58 0.56 0.56
EBIT Margin 0.31 0.33 0.34 0.34 0.32
Profit Margin 0.17 0.21 0.21 0.20 0.22
EBITDA 5.63 Billion 5.72 Billion 5.06 Billion 4.69 Billion 4.58 Billion
Earnings Before Tax Margin 0.22 0.26 0.26 0.26 0.25

Income Statement Charts